Kamari Pharma, a Rehovot, Israel-based developer of topical and oral drugs, raised $8M in funding.
The round was led by GIBF2.
The company intends to use the funds to accelerate growth and its development efforts.
Established at the end of 2018 by Israeli based biotechnology funds Pontifax and Arkin Bioholdings, Kamari develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These innovative drugs are intended for the treatment of various dermatological diseases, such as keratoderma, Lichen Simplex Chronicus and other severe genetic skin disorders. The Chairman of Kamari is Prof. David Aviezer, previously CEO of Protalix Biotherapeutics, who led it to its first FDA approval and listing on the New York Stock Exchange. Kamari is led by an experienced and professional management team, which includes Dr. Liora Braiman, CSO, and Asaf Yarkoni, CFO. It successfully completed the pre-clinical development of its first drug. Kamari is currently running clinical trials in patients in leading medical centers in Germany and Israel.